XNAS
DXR
Market cap61mUSD
Oct 08, Last price
10.46USD
1D
-0.48%
1Q
-0.66%
Jan 2017
26.90%
Name
Daxor Corp
Chart & performance
P/E
6.66
P/S
121.30
EPS
1.57
Div yield, %
—
Shrs. gr., 5y
4.84%
Rev. gr., 5y
-14.37%
Revenues
503k
-76.37%
Net income
9m
+1,609.71%
CFO
-604k
L
Dividend
Jan 05, 20180.03 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
Key people
Michael Feldschuh
Chairman of the Board, President, Chief Executive Officer · since 2017
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary · since 2018
John Jefferies
Chief Medical Officer · since 2025
Jonathan Feldschuh
Chief Scientific Officer, Director · since 2017
Henry Cremisi
Independent Director · since 2020
Caleb Desrosiers
Independent Director · since 2022
Edward Feuer
Independent Director · since 2016
Joy Goudie
Independent Director · since 2020
Headquarters & legal address
109 MECO LANE
OAK RIDGE, TN 37830
US
OAK RIDGE, TN 37830
US
Previous name
IDANT CORPORATION
Previous name
IATRIC CORPORATION
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||